Company Overview

Kashiv BioSciences is a fully-integrated biopharmaceutical company with global R&D, clinical, regulatory, and manufacturing capabilities. The company was originally formed as a specialty pharmaceutical business and has since transformed itself to develop and deploy its end-to-end biosimilars platform and aggressively expand its pipeline. In the first half of 2022, Kashiv validated its biosimilars platform after receiving FDA approvals for RELEUKO® (biosimilar to NEUPOGEN®) and FYLNETRA® (biosimilar to NEULASTA®).

We leverage our expertise in large and complex small molecules to continue building and advancing a differentiated pipeline of biosimilars, 505(b)(2), complex peptide generics, and mRNA therapies. We seek to commercialize our programs via strategic partnerships to maintain a deep focus on R&D and manufacturing.


Our mission is to develop clinically differentiated products and widely accessible, high-quality biosimilars to improve patients’ lives.


Our vision is to become a leading global biopharmaceutical company that develops and manufactures effective and differentiated therapeutics to meet unmet medical needs.